Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Henlius Biotech, Inc.
上海復宏漢霖生物技術股份有限公司
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 2696)

POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE 2025 SECOND EXTRAORDINARY GENERAL MEETING HELD ON MONDAY, 21 JULY 2025

The board (the "**Board**") of directors (the "**Directors**") of Shanghai Henlius Biotech, Inc. (the "**Company**") is pleased to announce the poll results of the 2025 second extraordinary general meeting (the "**EGM**") held at Conference Room, 10th Floor, B8 Building, No. 188 Yizhou Road, Xuhui District, Shanghai, PRC at 5:00 p.m. on Monday, 21 July 2025.

References are made to the notice and the circular (the "**Circular**") of the Company both dated 3 July 2025 in relation to the EGM. Unless the context otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

EGM

As at the date of the EGM, the total number of the issued shares of the Company (the "**Shares**") was 543,494,853 Shares, comprising 380,066,312 Unlisted Shares and 163,428,541 H Shares, all of which entitled the holders (or authorised representatives) to attend and vote on the resolutions proposed at the EGM (the "**Resolutions**"). Shareholders or authorised representatives holding an aggregate of 439,342,509 Shares with voting rights, representing approximately 80.836554% of the total number of the Shares with voting rights of the Company were present at the EGM. All Directors attended the EGM.

As disclosed in the Circular, Dr. Zhu, his associates and all other core connected persons of the Company were required to abstain from voting in favour on the relevant resolution with respect to the Conditional RSU Grant to Dr. Zhu (i.e. resolution No. 7) in accordance with the Listing Rules at the EGM. As at the date of the EGM, Dr. Zhu, his associates and all other core connected persons of the Company were interested in an aggregate of 346,512,336 Shares, representing approximately 63.756323% of the total issued Shares of the Company, and had abstained from voting on such resolution No. 7.

Save as disclosed above, to the best of the Directors' knowledge, information and belief, having made all reasonable enquiries, no Shareholder was required to abstain from voting on the Resolutions under the Listing Rules, and there was no Share entitling the holder to attend the EGM and abstain from voting in favour of the Resolutions under Rule 13.40 of the Listing Rules. Save as disclosed above, no Shareholder has stated the intention in the Circular to vote against or to abstain from voting on the Resolutions.

Pursuant to the Listing Rules and the articles of association of the Company (the "**Articles of Association**"), Computershare Hong Kong Investor Services Limited, representatives from the Shareholders and a member of the board of supervisors of the Company acted as the scrutineers for vote-tabulation at the EGM.

The EGM was convened in compliance with the requirements of the Company Law of PRC and the Articles of Association. Mr. Wenjie Zhang, chairman of the Board of the Company, acted as the chairman of the EGM.

POLL RESULTS OF THE EGM

The poll results in respect of the EGM Resolutions are as follows:

Ordinary Resolutions		**Number of valid votes and percentage of total number of votes (%)**		
		For	**Against**	**Abstain**
1.	To consider and approve the Share Option Scheme.	435,246,848 (99.067775%)	4,095,661 (0.932225%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
2.	To consider and approve the RSU Scheme.	435,246,848 (99.067775%)	4,095,661 (0.932225%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
3.	To consider and approve the Service Provider Sublimit for issuing not more than 1.5% of the total number of Shares in issue (excluding any treasury shares) as at the Adoption Date to Service Provider Participants under the Share Option Scheme and all options and awards under any other share scheme(s) of the Company (including the RSU Scheme), subject to the adoption of the Share Option Scheme.	434,688,748 (98.940744%)	4,653,761 (1.059256%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
4.	To consider and approve the Service Provider Sublimit for issuing not more than 1.5% of the total number of Shares in issue (excluding any treasury shares) as at the Adoption Date to Service Provider Participants under the RSU Scheme and all options and awards under any other share scheme(s) of the Company (including the Share Option Scheme), subject to the adoption of the RSU Scheme.	434,688,748 (98.940744%)	4,653,761 (1.059256%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

Ordinary Resolutions		Number of valid votes and percentage of total number of votes (%)		
		For	Against	Abstain
5.	To consider and approve the authorisation to the Board and/or the Scheme Administrator to handle matters relating to the Share Option Scheme.	435,246,848 (99.067775%)	4,095,661 (0.932225%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
6.	To consider and approve the authorisation to the Board and/or the Scheme Administrator to handle matters relating to the RSU Scheme.	435,246,848 (99.067775%)	4,095,661 (0.932225%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			
7.	To consider and approve the grant of 750,000 RSUs to Dr. Jun ZHU, subject to the adoption of the RSU Scheme.	89,957,948 (95.081200%)	4,653,761 (4.918800%)	0 (0.000000%)
	As more than half of the votes were cast in favour of this resolution, the resolution was duly passed as an ordinary resolution.			

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 21 July 2025

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the chairman and non-executive director, Dr. Jun Zhu as the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Dr. Xingli Wang as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.